Quanterix Corporation logo

Quanterix Corporation (QTRX)

Market Closed
8 Dec, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
7. 55
-0.08
-1.05%
After Hours
$
9. 31
+1.76 +23.31%
344.73M Market Cap
- P/E Ratio
0% Div Yield
854,624 Volume
-1 Eps
$ 7.63
Previous Close
Day Range
7.28 7.74
Year Range
4.05 12.41
Want to track QTRX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 14 days

Summary

QTRX closed today lower at $7.55, a decrease of 1.05% from yesterday's close, completing a monthly decrease of -2.2% or $0.17. Over the past 12 months, QTRX stock lost -30.48%.
QTRX is not paying dividends to its shareholders.
The last earnings report, released on Nov 10, 2025, exceeded the consensus estimates by 0.23%. On average, the company has surpassed earnings expectations by 0.13%, based on the last three reports. The next scheduled earnings report is due on Dec 22, 2025.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

QTRX Chart

Similar

Structure Therapeutics Inc.
$ 69.98
+102.49%
Procept BioRobotics Corporation
$ 34.03
-5.1%
Hillman Solutions Corp.
$ 8.7
-1.36%
Trevi Therapeutics Inc.
$ 12.98
-3.64%
MannKind Corporation
$ 5.63
-0.88%
Quanterix Corporation (QTRX) Q3 2025 Earnings Call Transcript

Quanterix Corporation (QTRX) Q3 2025 Earnings Call Transcript

Quanterix Corporation ( QTRX ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Joshua Young Masoud Toloue - President, CEO & Director Vandana Sriram - CFO & Treasurer Conference Call Participants Kyle Mikson - Canaccord Genuity Corp., Research Division Daniel Brennan - TD Cowen, Research Division Puneet Souda - Leerink Partners LLC, Research Division Tom DeBourcy - Nephron Research LLC Presentation Operator Hello, and thank you for standing by. My name is Tiffany, and I will be your conference operator today.

Seekingalpha | 3 weeks ago
Quanterix Corporation (QTRX) Reports Q3 Loss, Tops Revenue Estimates

Quanterix Corporation (QTRX) Reports Q3 Loss, Tops Revenue Estimates

Quanterix Corporation (QTRX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.22 per share a year ago.

Zacks | 3 weeks ago
Down 24.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Quanterix (QTRX)

Down 24.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Quanterix (QTRX)

Quanterix (QTRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks | 3 months ago

Quanterix Corporation (QTRX) FAQ

What is the stock price today?

The current price is $7.55.

On which exchange is it traded?

Quanterix Corporation is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is QTRX.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 344.73M.

When is the next earnings date?

The next earnings report will release on Dec 22, 2025.

Has Quanterix Corporation ever had a stock split?

No, there has never been a stock split.

Quanterix Corporation Profile

Health Care Technology Industry
Healthcare Sector
Masoud Toloue CEO
NASDAQ (NMS) Exchange
74766Q101 CUSIP
US Country
471 Employees
- Last Dividend
- Last Split
7 Dec 2017 IPO Date

Overview

Quanterix Corporation, situated in Billerica, Massachusetts, represents a significant force in the life sciences sector, focusing on the development and marketing of cutting-edge digital immunoassay platforms that propel precision health forward. Initially known as Digital Genomics, Inc., the company underwent a rebranding to Quanterix Corporation in August 2007, marking a new chapter in its mission to revolutionize life sciences research and diagnostics. Its operations span globally, reaching North America, Europe, the Middle East, Africa, and the Asia Pacific regions. Quanterix has carved a niche in fields like neurology, oncology, cardiology, infectious diseases, and inflammation, establishing its prominence by serving a diverse client base that includes academic and governmental research institutions, pharmaceutical, biotechnology, and contract research companies. Through direct sales, support organizations, and a network of distributors or sales agents, Quanterix ensures its innovative products and services are accessible to those dedicated to advancing healthcare and medical research.

Products and Services

HD-X Instrument: This flagship product from Quanterix stands out as a powerful protein detection platform. The HD-X Instrument is designed for researchers who require highly sensitive, accurate, and scalable solutions for protein quantification, making it a cornerstone in the advancement of precision health.

SR-X Instrument: The SR-X Instrument broadens the application landscape for Simoa detection technology, offering researchers an adaptable tool for their experimental designs. Its ability to facilitate a wide range of applications makes it a versatile addition to the scientific toolkit, especially for those pushing the boundaries of detection and quantification in complex biological samples.

SP-X Instrument: Focused on Simoa planar array technology, the SP-X Instrument is specialized in the measurement of multiplex chemiluminescent immunoassays. It represents Quanterix's commitment to providing high-throughput, sensitive solutions for researchers working with multiplex assays, enhancing efficiency and data quality in laboratories worldwide.

Assays and Components: Quanterix offers a comprehensive range of assays and components, including all elements required to run enzyme-based immunoassays such as beads, capture and detector reagents, enzyme reagents, and substrates. This extensive product line supports the scientific community by simplifying the procurement process and ensuring that high-quality components are readily available for a multitude of research purposes.

Contract Research Services: Beyond its product offerings, Quanterix extends its expertise through a variety of contract research services. These services encompass sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services, reflecting Quanterix's dedication to supporting research projects with tailored, comprehensive solutions. By leveraging its state-of-the-art technology and scientific acumen, Quanterix serves as a valuable partner for organizations seeking to accelerate their research and diagnostic capabilities.

Contact Information

Address: Building 1
Phone: 617 301 9400